Most Read Articles
Jairia Dela Cruz, 6 days ago
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Tristan Manalac, 6 days ago
Less than 15 percent of Singaporean adolescents get the recommended 8–10 hours of sleep on a school night, reports a recent study, noting that such short sleep duration is linked to symptoms of depression, overweight or obesity, and poorer self-rated health.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
6 days ago
Airway type 2 inflammation remains persistent in many asthmatics on inhaled corticosteroids, a new study has shown. These patients tend to be older and have a more severe disease.

Apremilast proven safe, effective for moderate hidradenitis suppurativa

4 days ago

Apremilast (30 mg twice daily) is clinically effective and generally well tolerated in patients with moderate hidradenitis suppurativa (HS), results of a randomized controlled trial have shown.

Eight of 15 patients (53.3 percent) in the apremilast group and none of five (0 percent) in the placebo group met the HS clinical response at week 16 (p=0.055).

In addition, patients treated with apremilast vs placebo had significantly lower abscess and nodule count (mean difference, –2.6; 95 percent CI, –6.0 to –0.9; p=0.011), numerical rating scale for pain (mean difference, –2.7; –4.5 to –0.9; p=0.009) and itch (mean difference, –2.8; –5.0 to –0.6; p=0.015) over 16 weeks.

No significant between-group difference was observed in the Dermatology Life Quality Index over time (mean difference, –3.4; –9.0 to 2.3; p=0.230). The most common adverse events in the apremilast group were mild-to-moderate headache and gastrointestinal symptoms, which did not lead to dropouts.

To assess the efficacy and short-term safety of apremilast, the investigators randomized in a 3:1 ratio a total of 20 patients with moderate HS to receive blinded treatment with apremilast 30 mg twice daily or placebo for 16 weeks.

The primary endpoint was the Hidradenitis Suppurativa Clinical Response at week 16. Secondary clinical outcomes between treatment groups were evaluated using linear mixed effects modeling (analysis of covariance). The study was limited by its small sample size and relatively short duration.

“Effective anti-inflammatory treatments for HS are limited,” the investigators said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 6 days ago
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Tristan Manalac, 6 days ago
Less than 15 percent of Singaporean adolescents get the recommended 8–10 hours of sleep on a school night, reports a recent study, noting that such short sleep duration is linked to symptoms of depression, overweight or obesity, and poorer self-rated health.
04 Jan 2019
Obstructive sleep apnoea may increase the risk of male-pattern baldness in men with a family history of hair loss, and this association appears to be mediated by low serum transferrin saturation levels related to hypoxia, a study suggests.
6 days ago
Airway type 2 inflammation remains persistent in many asthmatics on inhaled corticosteroids, a new study has shown. These patients tend to be older and have a more severe disease.